EP2016950B1
(en)
|
1996-08-08 |
2011-01-05 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical composition comprising an exendin-4 peptide
|
HU227021B1
(en)
*
|
1996-08-30 |
2010-05-28 |
Novo Nordisk As |
Glp-1 derivatives
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
US6380357B2
(en)
|
1997-12-16 |
2002-04-30 |
Eli Lilly And Company |
Glucagon-like peptide-1 crystals
|
ATE466027T1
(de)
|
1998-02-27 |
2010-05-15 |
Novo Nordisk As |
Abkömmlinge von glp-1 analogen
|
JP2002508162A
(ja)
*
|
1998-02-27 |
2002-03-19 |
ノボ ノルディスク アクティーゼルスカブ |
N末端を短縮したglp−1誘導体
|
AU3247799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
EP1840134B1
(en)
*
|
1998-02-27 |
2016-04-13 |
Novo Nordisk A/S |
GLP-1 derivatives
|
JP2002504518A
(ja)
*
|
1998-02-27 |
2002-02-12 |
ノボ ノルディスク アクティーゼルスカブ |
部分的に構造化されたミセルー様凝集体を形成する、25%を超えるヘリックス−含有率を有するglp−1誘導体
|
ATE466028T1
(de)
|
1998-02-27 |
2010-05-15 |
Novo Nordisk As |
N-terminal veränderte glp-1 abkömmlinge
|
CA2321026A1
(en)
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
AU5027299A
(en)
*
|
1998-07-31 |
2000-02-28 |
Novo Nordisk A/S |
Use of glp-1 and analogues for preventing type ii diabetes
|
EP1666054A1
(en)
*
|
1998-08-28 |
2006-06-07 |
Eli Lilly & Company |
Method for administering insulinotropic peptides
|
US6720407B1
(en)
|
1998-08-28 |
2004-04-13 |
Eli Lilly And Company |
Method for administering insulinotropic peptides
|
PL346317A1
(en)
*
|
1998-08-28 |
2002-01-28 |
Lilly Co Eli |
Method for administering insulinotropic peptides
|
US6440930B1
(en)
|
1998-09-17 |
2002-08-27 |
Eli Lilly And Company |
Protein formulations
|
MY155270A
(en)
*
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
PL189664B1
(pl)
*
|
1998-12-07 |
2005-09-30 |
Sod Conseils Rech Applic |
Nowy analog GLP-1, kompozycja farmaceutyczna go zawierająca oraz zastosowanie nowego analogu GLP-1
|
ATE394423T1
(de)
|
1998-12-07 |
2008-05-15 |
Sod Conseils Rech Applic |
Analoge des glucagon ähnlichen peptides-1 (glp-1)
|
CA2353574C
(en)
*
|
1998-12-07 |
2012-05-08 |
Zheng Xin Dong |
Analogues of glp-1
|
US6902744B1
(en)
*
|
1999-01-14 |
2005-06-07 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist formulations and methods of administration thereof
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
EP1163268B1
(en)
*
|
1999-03-15 |
2011-05-11 |
Novo Nordisk A/S |
Ion exchange chromatographic separation of glp-1 and related peptides
|
WO2000055119A1
(en)
*
|
1999-03-17 |
2000-09-21 |
Novo Nordisk A/S |
Method for acylating peptides and novel acylating agents
|
KR20020002480A
(ko)
*
|
1999-03-17 |
2002-01-09 |
한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 |
펩티드의 아실화법 및 신규한 아실화제
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
EP1175443A1
(en)
*
|
1999-04-30 |
2002-01-30 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
ES2209885T3
(es)
|
1999-05-17 |
2004-07-01 |
Conjuchem, Inc. |
Peptidos insulinotropicos de larga duracion.
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
EP1076066A1
(en)
*
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
AU1269501A
(en)
*
|
1999-11-12 |
2001-05-30 |
Novo Nordisk A/S |
Use of glp-1 agonists for the inhibition of beta cell degeneration
|
US6569832B1
(en)
|
1999-11-12 |
2003-05-27 |
Novo Nordisk A/S |
Inhibition of beta cell degeneration
|
US6844321B2
(en)
*
|
2000-01-31 |
2005-01-18 |
Novo Nordisk A/S |
Crystallization of a GLP-1 analogue
|
EP1263458B1
(en)
|
2000-03-08 |
2005-11-16 |
Novo Nordisk A/S |
Lowering serum cholesterol
|
DE10013895A1
(de)
|
2000-03-21 |
2001-10-04 |
Dmc2 Degussa Metals Catalysts Cerdec Ag |
Verfahren zur katalytischen Umsetzung von Kohlenmonoxid in einem Wasserstoff enthaltenden Gasgemisch
|
BR0113178A
(pt)
*
|
2000-08-02 |
2004-04-06 |
Theratechnologies Inc |
Peptìdeos biológicos modificados com potência aumentada
|
DE60136958D1
(de)
|
2000-12-01 |
2009-01-22 |
Takeda Pharmaceutical |
Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
|
BR0116024A
(pt)
*
|
2000-12-07 |
2005-12-13 |
Lilly Co Eli |
Proteìna de fusão heteróloga e uso da mesma
|
EP1345924B1
(de)
|
2000-12-21 |
2006-08-30 |
Sanofi-Aventis Deutschland GmbH |
Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
DE50111751D1
(de)
|
2000-12-21 |
2007-02-08 |
Sanofi Aventis Deutschland |
Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
|
AU2002235731A1
(en)
*
|
2001-03-07 |
2002-09-19 |
Novo Nordisk A/S |
Combined use of derivatives of glp-1 analogs and ppar ligands
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
DE10142660A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
WO2002088166A1
(en)
*
|
2001-05-02 |
2002-11-07 |
Novo Nordisk A/S |
Preparation of bile acids
|
US6653492B2
(en)
|
2001-05-02 |
2003-11-25 |
Novo Nordick A/S |
Preparation of bile acids
|
PE20021091A1
(es)
|
2001-05-25 |
2003-02-04 |
Aventis Pharma Gmbh |
Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
|
ES2298378T3
(es)
*
|
2001-06-28 |
2008-05-16 |
Novo Nordisk A/S |
Formulacion estable de glp-1 modificado.
|
US20030082671A1
(en)
|
2001-07-24 |
2003-05-01 |
Thomas Hoeg-Jensen |
Method for making acylated polypeptides
|
US7595172B2
(en)
*
|
2001-07-24 |
2009-09-29 |
Novo Nordisk A/S |
Method for making acylated polypeptides
|
OA12654A
(en)
|
2001-08-22 |
2006-06-15 |
Aventis Pharma Gmbh |
Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances,and the use thereof.
|
DE10142667B4
(de)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
|
DE10142659A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
US6884812B2
(en)
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
DE10142663B4
(de)
|
2001-08-31 |
2004-08-19 |
Aventis Pharma Deutschland Gmbh |
C2-Disubstituierte Indan-1-ol-Systeme
|
DE10142662B4
(de)
|
2001-08-31 |
2004-07-08 |
Aventis Pharma Deutschland Gmbh |
Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
|
DE10142665B4
(de)
|
2001-08-31 |
2004-05-06 |
Aventis Pharma Deutschland Gmbh |
C2-Disubstituierte Indan-1-one und ihre Derivate
|
DE10142661B4
(de)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
|
DE10142722A1
(de)
|
2001-08-31 |
2003-03-27 |
Aventis Pharma Gmbh |
C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10142668A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
DE10142666A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
EE05418B1
(et)
|
2001-08-31 |
2011-06-15 |
Aventis Pharma Deutschland Gmbh |
Diarltskloalklderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
|
US7399777B2
(en)
|
2001-08-31 |
2008-07-15 |
Sanofi-Aventis Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
|
IL160983A0
(en)
|
2001-09-24 |
2004-08-31 |
Imp College Innovations Ltd |
Use of pyy for preparation of a medicament for modification of feeding behavior
|
WO2003031432A1
(en)
|
2001-10-12 |
2003-04-17 |
Novo Nordisk A/S |
Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
MXPA04003553A
(es)
*
|
2001-10-18 |
2004-07-22 |
Bristol Myers Squibb Co |
Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas.
|
KR101018318B1
(ko)
|
2001-12-21 |
2011-03-04 |
노보 노르디스크 에이/에스 |
Gk 활성제로서의 아미드 유도체
|
JP2005518408A
(ja)
|
2001-12-29 |
2005-06-23 |
ノボ ノルディスク アクティーゼルスカブ |
異常脂肪血症を治療するための、glp−1化合物と他の薬物との組み合わせ使用
|
AR038102A1
(es)
*
|
2002-01-08 |
2004-12-29 |
Lilly Co Eli |
Analogos extendidos de peptido 1 de tipo glucagon
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
EP1474163A2
(en)
*
|
2002-01-10 |
2004-11-10 |
Imperial College Innovations Limited |
Modification of feeding behavior
|
US20050148497A1
(en)
|
2002-02-20 |
2005-07-07 |
Khan Mohammed A. |
Method for administering glp-1 molecules
|
US7223796B2
(en)
|
2002-04-11 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7049341B2
(en)
|
2002-06-07 |
2006-05-23 |
Aventis Pharma Deutschland Gmbh |
N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
|
US7176193B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7176194B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7671047B2
(en)
|
2002-06-19 |
2010-03-02 |
Sanofi-Aventis Deutschland Gmbh |
Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
EP1531815B1
(en)
|
2002-06-27 |
2014-09-24 |
Novo Nordisk A/S |
Glucokinase activators
|
ATE432289T1
(de)
*
|
2002-07-04 |
2009-06-15 |
Zealand Pharma As |
Glp-1 und behandlungsmethode für diabetes
|
US7262220B2
(en)
|
2002-07-11 |
2007-08-28 |
Sanofi-Aventis Deutschland Gmbh |
Urea- and urethane-substituted acylureas, process for their preparation and their use
|
DE10231370B4
(de)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
ATE452879T1
(de)
|
2002-07-12 |
2010-01-15 |
Sanofi Aventis Deutschland |
Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
US7141561B2
(en)
|
2002-07-25 |
2006-11-28 |
Sanofi-Aventis Deutschland Gmbh |
Substituted diaryl heterocycles, process for their preparation and their use as medicaments
|
US8821915B2
(en)
|
2002-08-09 |
2014-09-02 |
Veroscience, Llc |
Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
|
AU2003271452A1
(en)
*
|
2002-09-25 |
2004-04-19 |
Theratechnologies Inc. |
Modified glp-1 peptides with increased biological potency
|
US7273921B2
(en)
|
2002-09-25 |
2007-09-25 |
Novo Nordisk A/S |
Method for producing acylated peptides
|
PL210455B1
(pl)
*
|
2002-09-25 |
2012-01-31 |
Novo Nordisk As |
Sposób otrzymywania acylowanych peptydów
|
US20040157922A1
(en)
|
2002-10-04 |
2004-08-12 |
Aventis Pharma Deutschland Gmbh |
Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
|
US7208504B2
(en)
|
2002-10-12 |
2007-04-24 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic inhibitors of hormone sensitive lipase
|
US7411039B2
(en)
|
2002-10-14 |
2008-08-12 |
Novo Nordisk A/S |
GLP-2 compounds, formulations, and uses thereof
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US7314859B2
(en)
|
2002-12-27 |
2008-01-01 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
US7655618B2
(en)
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
US20040242583A1
(en)
|
2003-01-20 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
|
US7179941B2
(en)
|
2003-01-23 |
2007-02-20 |
Sanofi-Aventis Deutschland Gmbh |
Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
|
WO2004069314A1
(en)
|
2003-02-04 |
2004-08-19 |
Novo Nordisk A/S |
Injection device with rotatable dose setting
|
WO2004089470A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
New amide derivatives and pharmaceutical use thereof
|
US7390814B2
(en)
|
2003-02-13 |
2008-06-24 |
Sanofi-Aventis Deutschland Gmbh |
Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
|
US7652007B2
(en)
|
2003-02-13 |
2010-01-26 |
Sanofi-Aventis Deutschland Gmbh |
Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
|
DE10306250A1
(de)
|
2003-02-14 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308355A1
(de)
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
DE10308353A1
(de)
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308351A1
(de)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308352A1
(de)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
US7501440B2
(en)
|
2003-03-07 |
2009-03-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
|
WO2004078195A1
(ja)
|
2003-03-07 |
2004-09-16 |
Ajinomoto Co., Inc. |
腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
|
SI1605897T1
(sl)
|
2003-03-19 |
2012-11-30 |
Lilly Co Eli |
Polietilen glikol povezane GLP spojine
|
AU2004225649B2
(en)
*
|
2003-03-28 |
2008-11-06 |
National Institute Of Agrobiological Sciences |
Process for producing plant storage organ with high production of recombinant protein and novel recombinant protein
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
CA2820537C
(en)
|
2003-04-23 |
2015-10-20 |
Valeritas, Inc. |
Hydraulically actuated pump for fluid administration
|
CN102940879B
(zh)
|
2003-06-03 |
2017-06-06 |
诺沃挪第克公司 |
稳定化的药物肽组合物
|
WO2004105790A1
(en)
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
RU2006103860A
(ru)
|
2003-08-21 |
2006-07-27 |
Ново Нордиск А/С (DK) |
Способ разделения полипептидов, содержащих рацемическую аминокислоту
|
WO2005023291A2
(en)
*
|
2003-09-11 |
2005-03-17 |
Novo Nordisk A/S |
Use of glp1-agonists in the treatment of patients with type i diabetes
|
CN100444898C
(zh)
*
|
2003-09-19 |
2008-12-24 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
EP1684793B1
(en)
*
|
2003-11-13 |
2011-09-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
CA2545034C
(en)
|
2003-11-20 |
2013-03-05 |
Novo Nordisk A/S |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
EP1694356B1
(en)
|
2003-12-09 |
2011-02-16 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
JP2007536214A
(ja)
*
|
2003-12-16 |
2007-12-13 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1類似体
|
US7521527B2
(en)
|
2003-12-16 |
2009-04-21 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
GLP-1 pharmaceutical compositions
|
CA2549582A1
(en)
|
2003-12-18 |
2005-06-30 |
Novo Nordisk A/S |
Novel glp-1 compounds
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
AU2005203930C1
(en)
|
2004-01-06 |
2012-02-23 |
Vtv Therapeutics Llc |
Heteroaryl-ureas and their use as glucokinase activators
|
CA2552526A1
(en)
*
|
2004-01-08 |
2005-07-21 |
Theratechnologies Inc. |
Glucagon-like peptide-1 analogs with long duration of action
|
ATE550041T1
(de)
|
2004-01-21 |
2012-04-15 |
Novo Nordisk Healthcare Ag |
Transglutaminase-vermittelte konjugation von peptiden
|
US7241787B2
(en)
|
2004-01-25 |
2007-07-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
|
US7498341B2
(en)
|
2004-01-31 |
2009-03-03 |
Sanofi Aventis Deutschland Gmbh |
Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7470706B2
(en)
|
2004-01-31 |
2008-12-30 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7402674B2
(en)
|
2004-01-31 |
2008-07-22 |
Sanofi-Aventis Deutschland Gmbh, |
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
DE102004005172A1
(de)
|
2004-02-02 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
|
KR100564618B1
(ko)
|
2004-03-11 |
2006-03-28 |
삼성전자주식회사 |
디스크 드라이브의 층간 탐색 방법
|
GT200500063A
(es)
|
2004-04-01 |
2005-10-14 |
|
Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
|
EP1586573B1
(en)
|
2004-04-01 |
2007-02-07 |
Sanofi-Aventis Deutschland GmbH |
Oxadiazolones, processes for their preparation and their use as pharmaceuticals
|
EP1604988A1
(en)
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
|
JP2008501765A
(ja)
|
2004-06-11 |
2008-01-24 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1アゴニストを用いた薬剤誘発性肥満の中和
|
WO2006014425A1
(en)
|
2004-07-02 |
2006-02-09 |
Biovalve Technologies, Inc. |
Methods and devices for delivering glp-1 and uses thereof
|
ES2442223T3
(es)
|
2004-08-31 |
2014-02-10 |
Novo Nordisk A/S |
Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
|
WO2006028970A1
(en)
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
JP2008515856A
(ja)
*
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性glp−1化合物
|
EP2330126B1
(en)
|
2004-10-07 |
2015-12-23 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
PL1817048T3
(pl)
|
2004-11-12 |
2014-07-31 |
Novo Nordisk As |
Stabilne preparaty peptydów insulinotropowych
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
US8148412B2
(en)
|
2004-12-03 |
2012-04-03 |
Novo Nordisk A/S |
Heteroaromatic glucokinase activators
|
TWI376234B
(en)
|
2005-02-01 |
2012-11-11 |
Msd Oss Bv |
Conjugates of a polypeptide and an oligosaccharide
|
WO2006082204A1
(en)
|
2005-02-02 |
2006-08-10 |
Novo Nordisk A/S |
Insulin derivatives
|
EP1846447B1
(en)
|
2005-02-02 |
2013-08-21 |
Novo Nordisk A/S |
Insulin derivatives
|
TWI372629B
(en)
*
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
KR20070120112A
(ko)
|
2005-03-18 |
2007-12-21 |
노보 노르디스크 에이/에스 |
연장형 glp-1 화합물
|
US8840586B2
(en)
|
2006-08-23 |
2014-09-23 |
Medtronic Minimed, Inc. |
Systems and methods allowing for reservoir filling and infusion medium delivery
|
US8512288B2
(en)
|
2006-08-23 |
2013-08-20 |
Medtronic Minimed, Inc. |
Infusion medium delivery device and method with drive device for driving plunger in reservoir
|
US8277415B2
(en)
|
2006-08-23 |
2012-10-02 |
Medtronic Minimed, Inc. |
Infusion medium delivery device and method with drive device for driving plunger in reservoir
|
US7955305B2
(en)
|
2005-05-06 |
2011-06-07 |
Medtronic Minimed, Inc. |
Needle inserter and method for infusion device
|
US8137314B2
(en)
|
2006-08-23 |
2012-03-20 |
Medtronic Minimed, Inc. |
Infusion medium delivery device and method with compressible or curved reservoir or conduit
|
US20080097291A1
(en)
|
2006-08-23 |
2008-04-24 |
Hanson Ian B |
Infusion pumps and methods and delivery devices and methods with same
|
US7905868B2
(en)
|
2006-08-23 |
2011-03-15 |
Medtronic Minimed, Inc. |
Infusion medium delivery device and method with drive device for driving plunger in reservoir
|
TW200722088A
(en)
*
|
2005-05-27 |
2007-06-16 |
Sankyo Co |
Diabetes remedy
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
JP5052511B2
(ja)
|
2005-06-30 |
2012-10-17 |
ハイ ポイント ファーマシューティカルズ,エルエルシー |
Pparデルタ活性化因子としてのフェノキシ酢酸
|
EP2233470B1
(en)
|
2005-07-04 |
2011-12-07 |
High Point Pharmaceuticals, LLC |
Histamine H3 receptor antagonists
|
EP2377856A1
(en)
|
2005-07-14 |
2011-10-19 |
Novo Nordisk A/S |
Urea glucokinase activators
|
WO2007015805A1
(en)
|
2005-07-20 |
2007-02-08 |
Eli Lilly And Company |
1-amino linked compounds
|
ES2397289T3
(es)
|
2005-09-22 |
2013-03-06 |
Biocompatibles Uk Ltd. |
Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
|
WO2007123581A1
(en)
|
2005-11-17 |
2007-11-01 |
Eli Lilly And Company |
Glucagon receptor antagonists, preparation and therapeutic uses
|
EP2364735A3
(en)
|
2005-12-16 |
2012-04-11 |
Nektar Therapeutics |
Branched PEG conjugates of GLP-1
|
BRPI0620468A2
(pt)
|
2005-12-22 |
2011-11-08 |
Transtech Pharma Inc |
ácidos fenóxi acéticos como ativadores de ppar delta
|
KR101728868B1
(ko)
|
2006-01-18 |
2017-05-02 |
포시 파마슈티컬스 컴퍼니 리미티드 |
안정성이 강화된 약학 조성물
|
US11497846B2
(en)
|
2006-02-09 |
2022-11-15 |
Deka Products Limited Partnership |
Patch-sized fluid delivery systems and methods
|
US11364335B2
(en)
|
2006-02-09 |
2022-06-21 |
Deka Products Limited Partnership |
Apparatus, system and method for fluid delivery
|
AU2007212275B2
(en)
|
2006-02-09 |
2013-03-21 |
Deka Products Limited Partnership |
Peripheral systems
|
US11478623B2
(en)
|
2006-02-09 |
2022-10-25 |
Deka Products Limited Partnership |
Infusion pump assembly
|
US11027058B2
(en)
|
2006-02-09 |
2021-06-08 |
Deka Products Limited Partnership |
Infusion pump assembly
|
MX2008011633A
(es)
|
2006-03-13 |
2008-12-16 |
Activx Biosciences Inc |
Aminoquinolonas como inhibidores de gsk-3.
|
JP5312054B2
(ja)
|
2006-03-15 |
2013-10-09 |
ノボ・ノルデイスク・エー/エス |
アミリンとインスリンの混合物
|
NZ570524A
(en)
|
2006-03-28 |
2011-08-26 |
High Point Pharmaceuticals Llc |
Benzothiazoles having histamine H3 receptor activity
|
CN101460216B
(zh)
|
2006-03-30 |
2013-06-19 |
瓦莱里塔斯公司 |
多筒式流体递送器械
|
BRPI0710468A2
(pt)
|
2006-04-24 |
2011-08-16 |
Lilly Co Eli |
composto, e, composição farmacêutica
|
EP1854455B1
(en)
|
2006-05-10 |
2009-10-07 |
Biocompatibles UK Limited |
Spherical microcapsules comprising GLP-1 peptides, their production and use
|
MX2008014766A
(es)
|
2006-05-29 |
2009-03-06 |
High Point Pharmaceuticals Llc |
3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)-piperazi na, sus sales y solvatos y su uso como antagonista del receptor de h3 histamina.
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
DK2054073T3
(da)
|
2006-07-11 |
2015-03-02 |
Foresee Pharmaceuticals Inc |
Farmaceutiske præparater til fremføring med langvarig frigivelse af peptider
|
US20090325873A1
(en)
|
2006-07-18 |
2009-12-31 |
Centocor, Inc. |
Human glp-1 mimetibodies, compositions, methods and uses
|
CA2666193A1
(en)
|
2006-08-08 |
2008-02-14 |
Sanofi-Aventis |
Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
|
US7794434B2
(en)
|
2006-08-23 |
2010-09-14 |
Medtronic Minimed, Inc. |
Systems and methods allowing for reservoir filling and infusion medium delivery
|
US7828764B2
(en)
|
2006-08-23 |
2010-11-09 |
Medtronic Minimed, Inc. |
Systems and methods allowing for reservoir filling and infusion medium delivery
|
US7811262B2
(en)
|
2006-08-23 |
2010-10-12 |
Medtronic Minimed, Inc. |
Systems and methods allowing for reservoir filling and infusion medium delivery
|
US7682338B2
(en)
|
2006-08-23 |
2010-03-23 |
Medtronic Minimed, Inc. |
Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
|
US20100056428A1
(en)
|
2006-09-01 |
2010-03-04 |
Novo Nordisk Health Care Ag |
Modified proteins
|
EA200900392A1
(ru)
|
2006-09-07 |
2010-06-30 |
Никомед Гмбх |
Комбинированное лечение сахарного диабета
|
US8022066B2
(en)
|
2006-11-15 |
2011-09-20 |
High Point Pharmaceuticals, Llc |
2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
CA2675111C
(en)
|
2007-01-11 |
2016-04-05 |
Novo Nordisk A\S |
Urea glucokinase activators
|
DE102007002260A1
(de)
|
2007-01-16 |
2008-07-31 |
Sanofi-Aventis |
Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
EP1975176A1
(en)
*
|
2007-03-27 |
2008-10-01 |
Biocompatibles UK Limited |
Novel glp-1 fusion peptides, their production and use
|
US8323250B2
(en)
|
2007-04-30 |
2012-12-04 |
Medtronic Minimed, Inc. |
Adhesive patch systems and methods
|
US8613725B2
(en)
|
2007-04-30 |
2013-12-24 |
Medtronic Minimed, Inc. |
Reservoir systems and methods
|
US8434528B2
(en)
|
2007-04-30 |
2013-05-07 |
Medtronic Minimed, Inc. |
Systems and methods for reservoir filling
|
US7959715B2
(en)
|
2007-04-30 |
2011-06-14 |
Medtronic Minimed, Inc. |
Systems and methods allowing for reservoir air bubble management
|
US8597243B2
(en)
|
2007-04-30 |
2013-12-03 |
Medtronic Minimed, Inc. |
Systems and methods allowing for reservoir air bubble management
|
WO2008136845A2
(en)
|
2007-04-30 |
2008-11-13 |
Medtronic Minimed, Inc. |
Reservoir filling, bubble management, and infusion medium delivery systems and methods with same
|
US7963954B2
(en)
|
2007-04-30 |
2011-06-21 |
Medtronic Minimed, Inc. |
Automated filling systems and methods
|
AU2008259342B2
(en)
|
2007-06-04 |
2014-07-10 |
Ben-Gurion University Of The Negev Research And Development Authority |
Tri-aryl compounds and compositions comprising the same
|
US20080319221A1
(en)
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
EP2170945A1
(en)
|
2007-07-16 |
2010-04-07 |
Novo Nordisk A/S |
Protease stabilized, pegylated insulin analogues
|
JP2009019027A
(ja)
*
|
2007-07-16 |
2009-01-29 |
Hanmi Pharmaceutical Co Ltd |
アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
EP2190460B1
(en)
|
2007-09-05 |
2014-12-17 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
EP2190872B1
(en)
|
2007-09-05 |
2018-03-14 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
CA2699151A1
(en)
|
2007-09-11 |
2009-03-19 |
Activx Biosciences, Inc. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
|
KR101597841B1
(ko)
|
2007-09-12 |
2016-02-26 |
교린 세이야꾸 가부시키 가이샤 |
Gsk-3 억제제로서의 스피로시클릭 아미노퀴놀론
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
HUE030383T2
(en)
|
2007-11-16 |
2017-05-29 |
Novo Nordisk As |
Stable pharmaceutical formulations containing liraglutide and deglates
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
AU2008347241B2
(en)
|
2007-12-31 |
2014-09-18 |
Deka Products Limited Partnership |
Infusion pump assembly
|
US10080704B2
(en)
|
2007-12-31 |
2018-09-25 |
Deka Products Limited Partnership |
Apparatus, system and method for fluid delivery
|
US10188787B2
(en)
|
2007-12-31 |
2019-01-29 |
Deka Products Limited Partnership |
Apparatus, system and method for fluid delivery
|
EP3679969A3
(en)
|
2007-12-31 |
2020-09-30 |
DEKA Products Limited Partnership |
Infusion pump assembly
|
US8900188B2
(en)
|
2007-12-31 |
2014-12-02 |
Deka Products Limited Partnership |
Split ring resonator antenna adapted for use in wirelessly controlled medical device
|
US9456955B2
(en)
|
2007-12-31 |
2016-10-04 |
Deka Products Limited Partnership |
Apparatus, system and method for fluid delivery
|
US8881774B2
(en)
|
2007-12-31 |
2014-11-11 |
Deka Research & Development Corp. |
Apparatus, system and method for fluid delivery
|
CN102007143B
(zh)
|
2008-01-09 |
2015-08-26 |
塞诺菲-安万特德国有限公司 |
具有超延迟时效特征的新型胰岛素衍生物
|
DE102008025008A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008025007A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
JP5695909B2
(ja)
|
2008-01-09 |
2015-04-08 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
|
US20110046071A1
(en)
*
|
2008-03-05 |
2011-02-24 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer
|
WO2009115469A1
(en)
|
2008-03-18 |
2009-09-24 |
Novo Nordisk A/S |
Protease stabilized, acylated insulin analogues
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
CN101555214B
(zh)
|
2008-04-08 |
2012-07-11 |
北京嘉事联博医药科技有限公司 |
苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
|
EP4074327A1
(en)
|
2008-06-27 |
2022-10-19 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
AR072707A1
(es)
|
2008-07-09 |
2010-09-15 |
Sanofi Aventis |
Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
|
CA2733200A1
(en)
|
2008-08-06 |
2010-02-11 |
Novo Nordisk Health Care Ag |
Conjugated proteins with prolonged in vivo efficacy
|
JP5591243B2
(ja)
|
2008-09-12 |
2014-09-17 |
ノボ・ノルデイスク・エー/エス |
ペプチド又はタンパク質のアシル化の方法
|
CA2954728C
(en)
|
2008-09-15 |
2019-03-26 |
Deka Products Limited Partnership |
Systems and methods for fluid delivery
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
RS56632B1
(sr)
|
2008-10-17 |
2018-03-30 |
Sanofi Aventis Deutschland |
Kombinacija insulina i glp-1-agonista
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
WO2010054326A2
(en)
|
2008-11-07 |
2010-05-14 |
The General Hospital Corporation |
C-terminal fragments of glucagon-like peptide-1 (glp-1)
|
IT1392655B1
(it)
|
2008-11-20 |
2012-03-16 |
Bio Ker S R L |
Site-specific monoconjugated insulinotropic glp-1 peptides.
|
CN102223797A
(zh)
|
2008-11-21 |
2011-10-19 |
高点制药有限责任公司 |
金刚烷基苯甲酰胺化合物
|
BRPI0922689A2
(pt)
|
2008-12-05 |
2018-11-06 |
Angiochem Inc. |
conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
EA020537B1
(ru)
|
2008-12-15 |
2014-11-28 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
AU2008365559B2
(en)
|
2008-12-15 |
2016-02-25 |
Zealand Pharma A/S |
Glucagon analogues
|
ES2477880T3
(es)
|
2008-12-15 |
2014-07-18 |
Zealand Pharma A/S |
Análogos del glucagón
|
BRPI0823379A2
(pt)
|
2008-12-15 |
2015-07-14 |
Zealand Pharma As |
Análogos de glucagon
|
MX2011007736A
(es)
|
2009-01-22 |
2011-09-06 |
Novo Nordisk Healthcare Ag |
Compuestos de hormona del crecimiento estables.
|
EP2389190B1
(en)
|
2009-01-23 |
2018-09-19 |
Novo Nordisk A/S |
Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
|
CN102942626B
(zh)
*
|
2009-03-05 |
2015-11-04 |
江苏豪森医药集团有限公司 |
胰高血糖素样肽-2类似物及其制备方法和用途
|
EP2406266B1
(en)
|
2009-03-11 |
2013-12-25 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as gsk-3 inhibitors
|
EP2437732B1
(en)
*
|
2009-06-05 |
2018-05-09 |
VeroScience LLC |
Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
|
US9352025B2
(en)
|
2009-06-05 |
2016-05-31 |
Veroscience Llc |
Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
|
AU2014265118B2
(en)
*
|
2009-06-05 |
2016-11-17 |
Veroscience Llc |
Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
|
WO2010142665A1
(en)
*
|
2009-06-11 |
2010-12-16 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
US9156901B2
(en)
|
2009-07-13 |
2015-10-13 |
Ditte Riber |
Acylated glucagon analogues
|
JP5961111B2
(ja)
|
2009-07-15 |
2016-08-02 |
デカ・プロダクツ・リミテッド・パートナーシップ |
注入ポンプアセンブリのための装置、システム、および方法
|
CN101987868B
(zh)
|
2009-07-30 |
2013-09-04 |
江苏豪森医药集团有限公司 |
Glp-1类似物的衍生物或其可药用盐和用途
|
US8614182B2
(en)
|
2009-07-30 |
2013-12-24 |
Jiangsu Hansoh Pharmaceuticals Co., Ltd. |
GLP-1 analogues and their pharmaceutical salts and uses
|
CN102612376A
(zh)
|
2009-08-06 |
2012-07-25 |
诺沃-诺迪斯克保健股份有限公司 |
具有延长的体内功效的生长激素
|
DK2470552T3
(en)
|
2009-08-26 |
2014-02-17 |
Sanofi Sa |
NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
|
JP2013506635A
(ja)
|
2009-10-02 |
2013-02-28 |
サノフイ |
骨疾患を処置するための薬剤を製造するためのsglt−1/sglt−2阻害剤活性を有する化合物の使用
|
EP2491054A2
(en)
|
2009-10-22 |
2012-08-29 |
Cadila Healthcare Limited |
Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
|
PT3345593T
(pt)
|
2009-11-13 |
2023-11-27 |
Sanofi Aventis Deutschland |
Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
|
ES2855146T3
(es)
|
2009-11-13 |
2021-09-23 |
Sanofi Aventis Deutschland |
Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
|
CN102791731B
(zh)
|
2009-12-16 |
2016-04-20 |
诺沃—诺迪斯克有限公司 |
Glp-1类似物和衍生物
|
WO2011091265A1
(en)
|
2010-01-22 |
2011-07-28 |
Deka Products Limited Partnership |
Method and system for shape-memory alloy wire control
|
CA2787895A1
(en)
|
2010-01-22 |
2011-07-28 |
Novo Nordisk Health Care Ag |
Stable growth hormone compounds
|
JP5875527B2
(ja)
|
2010-01-22 |
2016-03-02 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
in−vivoにおける効力が延長された成長ホルモン
|
US20130012432A1
(en)
|
2010-02-26 |
2013-01-10 |
Novo Nordisk A/S |
Peptides for Treatment of Obesity
|
BR112012021231A2
(pt)
|
2010-02-26 |
2015-09-08 |
Basf Plant Science Co Gmbh |
método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
|
US9422330B2
(en)
*
|
2010-03-01 |
2016-08-23 |
Novo Nordisk A/S |
Preparative RP-HPLC method for purifying peptides
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US20130035285A1
(en)
|
2010-03-26 |
2013-02-07 |
Novo Nordisk A/S |
Novel glucagon analogues
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
JP5969461B2
(ja)
|
2010-04-27 |
2016-08-17 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用
|
CA2793715A1
(en)
|
2010-04-30 |
2011-11-03 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
CN103068841A
(zh)
|
2010-06-24 |
2013-04-24 |
西兰制药公司 |
胰高血糖素类似物
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
HUE031181T2
(en)
|
2010-08-30 |
2017-06-28 |
Sanofi Aventis Deutschland |
Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
|
WO2012061466A2
(en)
|
2010-11-02 |
2012-05-10 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
EP2637698B1
(en)
|
2010-11-09 |
2022-04-20 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
DK3326620T3
(da)
|
2010-12-16 |
2020-05-25 |
Novo Nordisk As |
Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
|
US20140045754A1
(en)
|
2011-01-19 |
2014-02-13 |
Joern Drustrup |
Glp-1 compositions
|
CN103298456A
(zh)
|
2011-01-19 |
2013-09-11 |
诺沃—诺迪斯克有限公司 |
Glp-1颗粒和组合物
|
US20140011733A1
(en)
|
2011-01-20 |
2014-01-09 |
Zealand Pharma A/S |
Combination of acylated glucagon analogues with insulin analogues
|
US10130684B2
(en)
|
2011-02-03 |
2018-11-20 |
Pharmedica Ltd. |
Oral dissolving films for insulin administration, for treating diabetes
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120050A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2012120058A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
WO2012120051A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
JP2014510739A
(ja)
|
2011-03-28 |
2014-05-01 |
ノヴォ ノルディスク アー/エス |
新規のグルカゴン類似体
|
RU2602601C2
(ru)
*
|
2011-04-12 |
2016-11-20 |
Ново Нордиск А/С |
Дважды ацилированные производные glp-1
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
WO2012153196A2
(en)
|
2011-05-10 |
2012-11-15 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
EP2729157B1
(en)
|
2011-07-06 |
2019-01-16 |
The General Hospital Corporation |
A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
|
CN103917241A
(zh)
|
2011-08-29 |
2014-07-09 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
CN103189389B
(zh)
*
|
2011-09-03 |
2017-08-11 |
深圳市健元医药科技有限公司 |
新的glp‑ⅰ类似物及其制备方法和用途
|
CN107266558A
(zh)
*
|
2011-09-06 |
2017-10-20 |
诺沃—诺迪斯克有限公司 |
Glp‑1衍生物
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013041678A1
(en)
|
2011-09-23 |
2013-03-28 |
Novo Nordisk A/S |
Novel glucagon analogues
|
TW201315742A
(zh)
|
2011-09-26 |
2013-04-16 |
Novartis Ag |
治療代謝病症之雙功能蛋白質
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2763691A1
(en)
|
2011-10-04 |
2014-08-13 |
Sanofi-Aventis Deutschland GmbH |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
HUE028568T2
(en)
|
2011-10-04 |
2016-12-28 |
Sanofi Aventis Deutschland |
For use in the treatment of constriction and / or obstruction of the lysine senate and pancreatic duct system
|
CA2853884A1
(en)
|
2011-11-03 |
2013-05-10 |
Zealand Pharma A/S |
Glp-1 receptor agonist peptide gastrin conjugates
|
WO2013083826A2
(en)
|
2011-12-09 |
2013-06-13 |
Novo Nordisk A/S |
Glp-1 agonists
|
CA2861000A1
(en)
|
2011-12-29 |
2013-07-04 |
Novo Nordisk A/S |
Dipeptide comprising a non-proteogenic amino acid
|
EP2814844B1
(en)
|
2012-02-15 |
2017-08-02 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
WO2013120554A1
(en)
|
2012-02-15 |
2013-08-22 |
Novo Nordisk A/S |
Antibodies that bind peptidoglycan recognition protein 1
|
WO2013134519A2
(en)
|
2012-03-07 |
2013-09-12 |
Deka Products Limited Partnership |
Apparatus, system and method for fluid delivery
|
AU2013234496B2
(en)
|
2012-03-22 |
2017-07-27 |
Novo Nordisk A/S |
Compositions of GLP-1 peptides and preparation thereof
|
EP2827845B1
(en)
|
2012-03-22 |
2018-12-26 |
Novo Nordisk A/S |
Compositions comprising a delivery agent and preparation thereof
|
SG11201407137PA
(en)
|
2012-05-03 |
2014-11-27 |
Zealand Pharma As |
Gip-glp-1 dual agonist compounds and methods
|
AU2013255752B2
(en)
|
2012-05-03 |
2017-11-09 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (GLP-2) analogues
|
US11274135B2
(en)
*
|
2012-05-08 |
2022-03-15 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives
|
CN104519902B
(zh)
*
|
2012-05-08 |
2017-10-27 |
诺和诺德股份有限公司 |
双酰化glp‑1衍生物
|
EP2664374A1
(en)
*
|
2012-05-15 |
2013-11-20 |
F. Hoffmann-La Roche AG |
Lysin-glutamic acid dipeptide derivatives
|
US9993430B2
(en)
|
2012-06-20 |
2018-06-12 |
Novo Nordisk A/S |
Tablet formulation comprising semaglutide and a delivery agent
|
CA2877056A1
(en)
|
2012-07-01 |
2014-01-09 |
Novo Nordisk A/S |
Use of long-acting glp-1 peptides
|
US20150157619A1
(en)
|
2012-07-10 |
2015-06-11 |
Takeda Pharmaceutical Company Limited |
Pharmaceutical preparation for injection
|
WO2014016300A1
(en)
|
2012-07-23 |
2014-01-30 |
Zealand Pharma A/S |
Glucagon analogues
|
FR2994848B1
(fr)
|
2012-08-30 |
2014-08-22 |
Univ Paris Curie |
Traitement de l'arthrose par les hormones incretines ou leurs analogues
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
JP2016500682A
(ja)
|
2012-10-17 |
2016-01-14 |
ノヴォ ノルディスク アー/エス |
経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸
|
IN2015DN03795A
(pt)
|
2012-10-24 |
2015-10-02 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
|
WO2014093696A2
(en)
|
2012-12-12 |
2014-06-19 |
Massachusetts Institute Of Technology |
Insulin derivatives for diabetes treatment
|
CN104902919B
(zh)
|
2012-12-21 |
2018-11-20 |
赛诺菲 |
Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂
|
CN103059127B
(zh)
*
|
2013-01-07 |
2014-12-17 |
天津嘉宏科技有限公司 |
Glp-1类似物及其制备方法与应用
|
US9707273B2
(en)
|
2013-03-01 |
2017-07-18 |
Fundació Hospital Universitari Vall D'hebron—Institut De Recerca |
Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
|
SG11201507226YA
(en)
|
2013-03-15 |
2015-10-29 |
Protagonist Therapeutics Inc |
Hepcidin analogues and uses therof
|
US11045523B2
(en)
|
2013-04-05 |
2021-06-29 |
Novo Nordisk Healthcare Ag |
Formulation of growth hormone albumin-binder conjugate
|
KR20160021758A
(ko)
|
2013-04-18 |
2016-02-26 |
노보 노르디스크 에이/에스 |
의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트
|
EP4309699A3
(en)
|
2013-07-03 |
2024-04-24 |
DEKA Products Limited Partnership |
Apparatus and system for fluid delivery
|
CN105451776B
(zh)
*
|
2013-08-15 |
2020-04-17 |
诺和诺德股份有限公司 |
Glp-1衍生物及其用途
|
GB201315335D0
(en)
|
2013-08-29 |
2013-10-09 |
Of Singapore |
Amino diacids containing peptide modifiers
|
BR112016008115B1
(pt)
|
2013-10-17 |
2024-03-12 |
Boehringer Ingelheim International Gmbh |
Análogos de glucagon acilados
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
JP6657101B2
(ja)
|
2013-11-05 |
2020-03-04 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
糖尿病及びそれから生じる疾患合併症の治療のための化合物
|
WO2015067715A2
(en)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
BR112016009995B1
(pt)
|
2013-11-06 |
2023-04-18 |
Zealand Pharma A/S |
Compostos agonistas triplos glucagon-glp-1-gip
|
EP3080150B1
(en)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/gip受體促效劑
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/升糖素受體促效劑
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
CN103884846B
(zh)
*
|
2014-03-06 |
2016-06-08 |
杭州九源基因工程有限公司 |
一种利拉鲁肽生物学活性的检测方法
|
US10689429B2
(en)
|
2014-04-07 |
2020-06-23 |
Novo Nordisk A/S |
Double-acylated GLP-1 compounds
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
RS60316B1
(sr)
|
2014-05-07 |
2020-07-31 |
Novo Nordisk As |
Lečenje dijabetesa tipa 1 korišćenjem glp-1 i anti-il-21
|
ES2890600T3
(es)
|
2014-05-16 |
2022-01-20 |
Protagonist Therapeutics Inc |
Péptidos de tioéter antagonistas de integrina alfa4beta7
|
CN106536547A
(zh)
|
2014-06-04 |
2017-03-22 |
诺和诺德股份有限公司 |
用于医疗用途的glp‑1/胰高血糖素受体共激动剂
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
CN104987383A
(zh)
*
|
2014-07-08 |
2015-10-21 |
四川百利药业有限责任公司 |
一种glp-1衍生物
|
GB2528436A
(en)
|
2014-07-15 |
2016-01-27 |
Lancaster Univ Business Entpr Ltd |
Treatment of neurological diseases
|
BR112017001010A2
(pt)
|
2014-07-17 |
2017-11-14 |
Protagonist Therapeutics Inc |
inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais
|
BR112016030947A2
(pt)
|
2014-07-17 |
2017-10-24 |
Novo Nordisk As |
mutagênese dirigida ao local de anticorpos trem-1 para diminuição de viscosidade
|
EP3189072B1
(en)
|
2014-09-05 |
2018-07-18 |
University of Copenhagen |
Gip peptide analogues
|
SG11201702553RA
(en)
|
2014-10-01 |
2017-04-27 |
Protagonist Therapeutics Inc |
NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
|
WO2016054445A1
(en)
|
2014-10-01 |
2016-04-07 |
Protagonist Therapeutics, Inc. |
Novel cyclic monomer and dimer peptides having integrin antagonist activity
|
EP3006045B3
(en)
|
2014-10-07 |
2021-03-17 |
Cyprumed GmbH |
Pharmaceutical formulations for the oral delivery of peptide or protein drugs
|
JP6898231B6
(ja)
|
2014-10-29 |
2021-07-28 |
ジーランド ファーマ アクティーゼルスカブ |
Gipアゴニスト化合物及び方法
|
CN106999602B
(zh)
|
2014-11-27 |
2022-02-01 |
诺和诺德股份有限公司 |
Glp-1衍生物及其用途
|
JP6970615B2
(ja)
|
2014-12-12 |
2021-11-24 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
インスリングラルギン/リキシセナチド固定比処方
|
RU2729011C2
(ru)
|
2014-12-23 |
2020-08-03 |
Ново Нордиск А/С |
Производные fgf21 и их применения
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
AU2016232218B2
(en)
|
2015-03-18 |
2020-09-10 |
Boehringer Ingelheim International Gmbh |
Amylin analogues
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
US10426818B2
(en)
|
2015-03-24 |
2019-10-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
ES2763329T3
(es)
|
2015-04-16 |
2020-05-28 |
Zealand Pharma As |
Análogo de glucagón acilado
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
|
US10787490B2
(en)
|
2015-07-15 |
2020-09-29 |
Protaganist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
US10905744B2
(en)
|
2015-10-07 |
2021-02-02 |
Cyprumed Gmbh |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
WO2017117411A1
(en)
|
2015-12-30 |
2017-07-06 |
Protagonist Therapeutics, Inc. |
Analogues of hepcidin mimetics with improved in vivo half lives
|
EP3205660A1
(en)
|
2016-02-10 |
2017-08-16 |
Polypeptide Laboratories Holding (PPL) AB |
Method for preparation of peptides with pswang linker
|
DK3405476T3
(da)
|
2016-01-20 |
2024-05-21 |
Polypeptide Laboratories Holding Ppl Ab |
Fremgangsmåde til fremstilling af peptider med psWANG linker
|
EP3196206A1
(en)
|
2016-01-20 |
2017-07-26 |
Lonza Ltd |
Method for preparation of liraglutide
|
EP3205664A1
(en)
|
2016-02-11 |
2017-08-16 |
Polypeptide Laboratories Holding (PPL) AB |
Method for preparation of liraglutide using bal linker
|
WO2017149070A1
(en)
|
2016-03-03 |
2017-09-08 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
CN108883158A
(zh)
|
2016-03-04 |
2018-11-23 |
诺和诺德股份有限公司 |
用于肾脏病况的利拉鲁肽
|
US20190070266A1
(en)
|
2016-03-04 |
2019-03-07 |
Novo Nordisk A/S |
Liraglutide in Diabetic Foot Ulcer
|
WO2017165676A1
(en)
|
2016-03-23 |
2017-09-28 |
Protagonist Therapeutics, Inc. |
METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS
|
CN109311960A
(zh)
|
2016-03-23 |
2019-02-05 |
巴切姆股份公司 |
胰高血糖素样肽1类似物的纯化方法
|
US11117946B2
(en)
|
2016-03-23 |
2021-09-14 |
Bachem Holding Ag |
Method for preparing glucagon-like peptides
|
TWI784968B
(zh)
|
2016-09-09 |
2022-12-01 |
丹麥商西蘭製藥公司 |
澱粉素類似物
|
WO2018057977A1
(en)
|
2016-09-23 |
2018-03-29 |
Delpor, Inc. |
Stable compositions for incretin mimetic compounds
|
WO2018065634A1
(en)
|
2016-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
|
WO2018096164A1
(en)
|
2016-11-28 |
2018-05-31 |
Novo Nordisk A/S |
Insulin degludec for treating diabetes
|
MA46890A
(fr)
|
2016-11-28 |
2021-04-28 |
Novo Nordisk As |
Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
|
US11278596B2
(en)
|
2016-11-28 |
2022-03-22 |
Novo Nordisk A/S |
Insulin degludec in cardiovascular conditions
|
US11285180B2
(en)
|
2016-12-06 |
2022-03-29 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
CA3044915A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
GB201621987D0
(en)
|
2016-12-22 |
2017-02-08 |
Archer Virgil L See Archer Sheri A Arecor Ltd |
Novel composition
|
JP2020514365A
(ja)
|
2017-03-15 |
2020-05-21 |
ノヴォ ノルディスク アー/エス |
メラノコルチン4受容体に結合可能な二環式化合物
|
WO2018210919A1
(en)
|
2017-05-17 |
2018-11-22 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
US11572399B2
(en)
|
2017-05-31 |
2023-02-07 |
University Of Copenhagen |
Long-acting GIP peptide analogues
|
TWI762706B
(zh)
|
2017-08-24 |
2022-05-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1組成物及其用途
|
JP2020533302A
(ja)
|
2017-09-10 |
2020-11-19 |
ノヴォ ノルディスク アー/エス |
肥満の治療において使用するためのmic−1およびglp−1
|
EP4092038A1
(en)
|
2017-09-11 |
2022-11-23 |
Protagonist Therapeutics, Inc. |
Opioid agonist peptides and uses thereof
|
WO2019120480A1
(en)
|
2017-12-19 |
2019-06-27 |
Novo Nordisk A/S |
Solubility of glp-1 peptide
|
ES2960687T3
(es)
|
2018-02-02 |
2024-03-06 |
Novo Nordisk As |
Composiciones sólidas que comprenden un agonista del GLP-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
|
EP3749345A4
(en)
|
2018-02-08 |
2022-04-06 |
Protagonist Therapeutics, Inc. |
CONJUGATED HEPCIDIN MIMETICS
|
EP3759120A1
(en)
|
2018-02-27 |
2021-01-06 |
Zp Spv 3 K/S |
Compstatin analogues and their medical uses
|
JP2021519594A
(ja)
|
2018-04-02 |
2021-08-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
抗trem−1抗体およびその使用
|
EP4364751A2
(en)
|
2018-04-05 |
2024-05-08 |
Sun Pharmaceutical Industries Limited |
Novel glp-1 analogues
|
WO2019193204A1
(en)
|
2018-04-06 |
2019-10-10 |
Cyprumed Gmbh |
Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
|
WO2019200594A1
(zh)
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
WO2019209963A1
(en)
|
2018-04-24 |
2019-10-31 |
Deka Products Limited Partnership |
Apparatus and system for fluid delivery
|
TWI829687B
(zh)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|
WO2019222072A1
(en)
*
|
2018-05-15 |
2019-11-21 |
Savior Lifetec Corporation |
Preparation method of liraglutide derivative
|
US20210221867A1
(en)
|
2018-05-15 |
2021-07-22 |
Novo Nordisk A/S |
Compounds Capable of Binding to Melanocortin 4 Receptor
|
US10905738B2
(en)
|
2018-07-05 |
2021-02-02 |
Biozeus Desenvolvimento De Produtos Biofarmacêuticos |
Synthetic peptides, prodrugs, pharmaceutical compositions and uses
|
WO2020053414A1
(en)
|
2018-09-14 |
2020-03-19 |
Novo Nordisk A/S |
Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
|
EP3891174A1
(en)
|
2018-12-03 |
2021-10-13 |
Antag Therapeutics ApS |
Modified gip peptide analogues
|
WO2020187770A1
(en)
|
2019-03-15 |
2020-09-24 |
Diet4Life Aps |
Combination of dietary peptides
|
EP3947451A1
(en)
|
2019-04-01 |
2022-02-09 |
Novo Nordisk A/S |
Antibodies directed against liraglutide and use thereof
|
MX2022000397A
(es)
|
2019-07-10 |
2022-04-25 |
Protagonist Therapeutics Inc |
Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
|
EP4272751A3
(en)
|
2019-08-27 |
2024-02-14 |
Zp Spv 3 K/S |
Compstatin analogues and their medical uses
|
AU2020377469A1
(en)
|
2019-11-06 |
2022-04-28 |
Novo Nordisk A/S |
GLP-1 receptor agonists in dementia
|
EP4054536A1
(en)
|
2019-11-07 |
2022-09-14 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
WO2021105393A1
(en)
|
2019-11-29 |
2021-06-03 |
Novo Nordisk A/S |
Processes for obtaining stable glp-1 compositions
|
CN111040022B
(zh)
|
2019-12-23 |
2021-12-14 |
万新医药科技(苏州)有限公司 |
针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
|
BR112022013042A2
(pt)
|
2019-12-30 |
2022-10-18 |
Gan & Lee Pharmaceuticals Co Ltd |
Composto da fórmula b, formulação farmacêutica, composição farmacêutica, método para tratar ou prevenir hiperglicemia, diabetes e/ou obesidade
|
CN118005736A
(zh)
|
2020-01-15 |
2024-05-10 |
詹森生物科技公司 |
介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
|
TW202140063A
(zh)
|
2020-02-18 |
2021-11-01 |
丹麥商諾佛 儂迪克股份有限公司 |
醫藥配方
|
US20230129788A1
(en)
|
2020-03-30 |
2023-04-27 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
WO2021198195A1
(en)
|
2020-03-30 |
2021-10-07 |
Zealand Pharma A/S |
Agonist combination
|
US11478533B2
(en)
|
2020-04-27 |
2022-10-25 |
Novo Nordisk A/S |
Semaglutide for use in medicine
|
US20230165939A1
(en)
|
2020-04-29 |
2023-06-01 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and histidine
|
EP4146221A1
(en)
|
2020-05-07 |
2023-03-15 |
Frederiksberg Hospital |
Treatment of hyperuricemia
|
EP4210680A1
(en)
|
2020-09-07 |
2023-07-19 |
Cyprumed GmbH |
Improved pharmaceutical formulations of glp-1 receptor agonists
|
CA3193453A1
(en)
|
2020-09-30 |
2022-04-07 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Polypeptide conjugates and methods of uses
|
AU2021383828A1
(en)
|
2020-11-20 |
2023-07-06 |
Janssen Pharmaceutica Nv |
Compositions of peptide inhibitors of interleukin-23 receptor
|
EP4281034A1
(en)
|
2021-01-24 |
2023-11-29 |
Forrest, Michael, David |
Inhibitors of atp synthase - cosmetic and therapeutic uses
|
FR3120189A1
(fr)
|
2021-03-01 |
2022-09-02 |
Farid Bennis |
Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
|
WO2023285334A1
(en)
|
2021-07-12 |
2023-01-19 |
Novo Nordisk A/S |
Novel fatty acid modified urocortin 2 derivatives and the uses thereof
|
WO2023012263A1
(en)
|
2021-08-04 |
2023-02-09 |
Novo Nordisk A/S |
Solid oral peptide formulations
|
AU2022339044A1
(en)
|
2021-09-03 |
2024-03-14 |
Zealand Pharma A/S |
Dosage regime
|
CA3231153A1
(en)
|
2021-09-08 |
2023-03-16 |
Kosuke Takemoto |
Medicine for prevention and treatment of diseases linked to anti-obesity activity
|
WO2023192873A1
(en)
*
|
2022-03-28 |
2023-10-05 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
WO2024061919A1
(en)
|
2022-09-19 |
2024-03-28 |
Zealand Pharma A/S |
Combination therapy
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|
EP4345104A1
(en)
|
2022-09-30 |
2024-04-03 |
Bachem Holding AG |
Method for preparing liraglutide
|